Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12880
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNayler, W Gen
dc.contributor.authorDillon, J Sen
dc.contributor.authorSturrock, W Jen
dc.date.accessioned2015-05-16T02:37:49Z
dc.date.available2015-05-16T02:37:49Z
dc.date.issued1988-02-01en
dc.identifier.citationClinical and Experimental Pharmacology & Physiology; 15(2): 93-103en
dc.identifier.govdoc2856052en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12880en
dc.description.abstract1. Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension. 2. Six weeks of chronic therapy with verapamil (50 mg/kg per day, orally) to produce a plasma level of 80-100 ng/ml in Sprague-Dawley rats depletes cardiac noradrenaline (NA) without apparently causing beta 1 adrenoceptor 'up' regulation. 3. The effect of verapamil on cardiac NA is rapidly reversed upon verapamil withdrawal. 4. Chronic therapy with nisoldipine (100 mg/kg per day, orally) had no effect on cardiac NA. 5. Verapamil (50 mg/kg per day, orally) and nisoldipine (100 mg/kg per day, orally) therapy for 6 weeks prevented the time-dependent increase in systolic blood pressure in SHR rats. 6. Binding studies with (-)[3H]-D888 (desmethoxyverapamil) indicated that the affinity of the phenylalkylamine binding sites is higher in hearts of SHR relative to hearts from age-matched (25 weeks) WKY and SD, without any change in density.en
dc.language.isoenen
dc.subject.otherAging.metabolismen
dc.subject.otherAniline Compounds.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCalcium Channel Blockers.pharmacologyen
dc.subject.otherCatecholamines.metabolismen
dc.subject.otherDihydroalprenolol.diagnostic useen
dc.subject.otherHeart.drug effectsen
dc.subject.otherHypertension.physiopathologyen
dc.subject.otherIn Vitro Techniquesen
dc.subject.otherMaleen
dc.subject.otherMembranes.drug effects.metabolismen
dc.subject.otherNisoldipine.blood.pharmacologyen
dc.subject.otherNorepinephrine.metabolismen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred Strainsen
dc.subject.otherRats, Inbred WKYen
dc.subject.otherReceptors, Adrenergic, beta.drug effects.metabolismen
dc.subject.otherVerapamil.blood.pharmacologyen
dc.titleCalcium antagonists and hypertension.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and Experimental Pharmacology & Physiologyen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages93-103en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2856052en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.